fda tirzepatide shortage resolved 2025 clarifies policies for compounders as national GLP-1 supply begins to stabilize FDA Ends Compounded GLP-1s: What

Semaglutide is a Glucagon-like Peptide-1 Agonist that stimulates the GLP-1 receptors in our body

Key Factors to Discuss with Your Doctor Before starting this combination, patients should have an open and thorough discussion with their healthcare provider

The I stands for Inositol, a vitamin-like substance that helps convert fats into other forms of energy and helps reduce insulin resistance

As a GLP-1 receptor agonist, semaglutide can impact glucose metabolism and the immune response , potentially increasing the risk of yeast infections

However, coverage still depends on the specific TRICARE plan, provider network, and whether the treatment is considered medically necessary